Cart
sales@molnova.com
Luxdegalutamide
CAS No. 2750830-09-0
Luxdegalutamide( —— )
Catalog No. M36626 CAS No. 2750830-09-0
Luxdegalutamide (ARV-766) is a novel, potent, and orally bioavailable proteolytic targeting chimera (PROTAC) protein degrader that degrades not only wild-type AR but also clinically relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 730 | In Stock |
|
| 10MG | 1121 | In Stock |
|
| 25MG | 1691 | In Stock |
|
| 50MG | 2158 | In Stock |
|
| 100MG | 2762 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameLuxdegalutamide
-
NoteResearch use only, not for human use.
-
Brief DescriptionLuxdegalutamide (ARV-766) is a novel, potent, and orally bioavailable proteolytic targeting chimera (PROTAC) protein degrader that degrades not only wild-type AR but also clinically relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.
-
DescriptionLuxdegalutamide (ARV-766) is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. Luxdegalutamide degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorPROTACs | Androgen Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2750830-09-0
-
Formula Weight807.95
-
Molecular FormulaC45H54FN7O6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (123.77 mM; Ultrasonic )
-
SMILESO([C@H]1C(C)(C)[C@H](NC(=O)C2=CC=C(C=C2)N3CCC(CN4CCN(CC4)C5=CC(F)=C(C(N[C@@H]6C(=O)NC(=O)CC6)=O)C=C5)CC3)C1(C)C)C7=CC(OC)=C(C#N)C=C7
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Petrylak D P, et al. A phase 2 expansion study of ARV-766, a PROTAC androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC)[J]. 2023.
molnova catalog
related products
-
TRH-SH Pro
TRH-SH Pro
-
TAK-981
TAK-981 is a selective the SUMOylation enzymatic cascade inhibitor, has potential immune-activating and antineoplastic activities.
-
Isorhyncophylline
Isorhyncophylline and rhyncophylline can directly inhibit the contractile responses induced by several agonists in small blood vessels of rat, they also can inhibit the hypertensive effect of angiotensin Ⅱ.
